Kyntra Bio Inc (NASDAQ:KYNB) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been given an average rating of “Moderate Buy” by the five research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $32.50.

KYNB has been the topic of several research analyst reports. Wall Street Zen raised Kyntra Bio from a “sell” rating to a “hold” rating in a report on Saturday, April 18th. Rodman & Renshaw assumed coverage on Kyntra Bio in a report on Tuesday, June 9th. They issued a “buy” rating and a $30.00 price objective for the company. Weiss Ratings reiterated a “sell (d)” rating on shares of Kyntra Bio in a research report on Tuesday, June 16th. Finally, Oppenheimer initiated coverage on Kyntra Bio in a report on Monday, July 6th. They issued an “outperform” rating and a $35.00 target price on the stock.

Hedge Funds Weigh In On Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. Renaissance Technologies LLC bought a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 27,481 shares of the company’s stock, valued at approximately $186,000. Renaissance Technologies LLC owned about 0.68% of Kyntra Bio at the end of the most recent quarter. 72.71% of the stock is currently owned by institutional investors and hedge funds.

Kyntra Bio Trading Up 0.3%

NASDAQ:KYNB opened at $7.01 on Friday. Kyntra Bio has a 12 month low of $6.32 and a 12 month high of $12.60. The company has a market cap of $28.39 million, a PE ratio of 0.17 and a beta of 1.02. The company has a 50 day simple moving average of $7.06 and a two-hundred day simple moving average of $7.24.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.